Towards Personalized Medicine in Psoriasis: Current Progress

References

• Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–212. doi:10.1111/jdv.13854
   PubMed Web of Science ®Google Scholar
• Reid C, Cordingley L, Warren RB, Griffiths CEM. Progress to date in advancing stratified medicine in psoriasis. Am J Clin Dermatol. 2020;21(5):619–626. doi:10.1007/s40257-020-00533-z
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Jo S-J, Naldi L, et al. A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. Br J Dermatol. 2018;179(1):173–181. doi:10.1111/bjd.16332
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, Camela E. Treating psoriasis in the elderly: biologics and small molecules. Expert Opin Biol Ther. 2022;1–18. doi:10.1080/14712598.2022.2089020
   Web of Science ®Google Scholar
• Raimondo A, Balato A, Megna M, Balato N. Limitations of current monoclonal antibodies for plaque-type psoriasis and an outlook for the future. Expert Opin Biol Ther. 2018;18(6):605–607. doi:10.1080/14712598.2018.1479738
   PubMed Web of Science ®Google Scholar
• Litman T. Personalized medicine-concepts, technologies, and applications in inflammatory skin diseases. APMIS. 2019;127(5):386–424. doi:10.1111/apm.12934
   PubMed Web of Science ®Google Scholar
• Osmola-Mańkowska A, Teresiak-Mikołajczak E, Skrzypczak-Zielińska M, Adamski Z. Genetic polymorphism in psoriasis and its meaning for the treatment efficacy in the future. Postep dermatologii i Alergol. 2018;35(4):331–337. doi:10.5114/ada.2018.77661
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC. Psoriasis in the perspective of predictive, preventive participatory and personalized medicine. J Dermatolog Treat. 2018;29(2):107–108. doi:10.1080/09546634.2018.1437739
   PubMed Web of Science ®Google Scholar
• Ryan C, Renfro L, Collins P, Kirby B, Rogers S. Clinical and genetic predictors of response to narrowband ultraviolet B for the treatment of chronic plaque psoriasis. Br J Dermatol. 2010;163(5):1056–1063. doi:10.1111/j.1365-2133.2010.09985.x
   PubMed Web of Science ®Google Scholar
• Gallais Sérézal I, Classon C, Cheuk S, et al. Resident T cells in resolved psoriasis steer tissue responses that stratify clinical outcome. J Invest Dermatol. 2018;138(8):1754–1763. doi:10.1016/j.jid.2018.02.030
   PubMed Web of Science ®Google Scholar
• Prieto-Pérez R, Cabaleiro T, Daudén E, Ochoa D, Román M, Abad-Santos F. Pharmacogenetics of topical and systemic treatment of psoriasis. Pharmacogenomics. 2013;14(13):1623–1634. doi:10.2217/pgs.13.163
   PubMed Web of Science ®Google Scholar
• Yélamos O, Puig L. Systemic methotrexate for the treatment of psoriasis. Expert Rev Clin Immunol. 2015;11(5):553–563. doi:10.1586/1744666X.2015.1026894
   PubMed Web of Science ®Google Scholar
• Hannoodee M, Mittal M Methotrexate; 2022.
   Google Scholar
• Puig L. Methotrexate: new therapeutic approaches. Actas Dermosifiliogr. 2014;105(6):583–589. doi:10.1016/j.ad.2012.11.017
   PubMedGoogle Scholar
• Chládek J, Grim J, Martínková J, et al. Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. Br J Clin Pharmacol. 2002;54(2):147–156. doi:10.1046/j.1365-2125.2002.01621.x
   PubMed Web of Science ®Google Scholar
• Hayashi H, Tazoe Y, Tsuboi S, et al. A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis. Drug Metab Pharmacokinet. 2013;28(2):164–168. doi:10.2133/dmpk.dmpk-12-nt-038
   PubMed Web of Science ®Google Scholar
• Ando Y, Shimada H, Matsumoto N, et al. Role of methotrexate polyglutamation and reduced folate carrier 1 (RFC1) gene polymorphisms in clinical assessment indexes. Drug Metab Pharmacokinet. 2013;28(5):442–445. doi:10.2133/dmpk.dmpk-12-rg-128
   PubMed Web of Science ®Google Scholar
• Chandran V, Siannis F, Rahman P, Pellett FJ, Farewell VT, Gladman DD. Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis. J Rheumatol. 2010;37(7):1508–1512. doi:10.3899/jrheum.091311
   PubMed Web of Science ®Google Scholar
• Yélamos O, Català A, Vilarrasa E, Roé E, Puig L. Acute severe methotrexate toxicity in patients with psoriasis: a case series and discussion. Dermatology. 2014;229(4):306–309. doi:10.1159/000366501
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith RL, Campalani E, et al. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br J Dermatol. 2009;160(2):438–441. doi:10.1111/j.1365-2133.2008.08898.x
   PubMed Web of Science ®Google Scholar
• Campalani E, Arenas M, Marinaki AM, Lewis CM, Barker JNWN, Smith CH. Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol. 2007;127(8):1860–1867. doi:10.1038/sj.jid.5700808
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith RLL, Campalani E, et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol. 2008;128(8):1925–1929. doi:10.1038/jid.2008.16
   PubMed Web of Science ®Google Scholar
• Ovejero-Benito MC, Muñoz-Aceituno E, Reolid A, Saiz-Rodríguez M, Abad-Santos F, Daudén E. Pharmacogenetics and pharmacogenomics in moderate-to-severe psoriasis. Am J Clin Dermatol. 2018;19(2):209–222. doi:10.1007/s40257-017-0322-9
   PubMed Web of Science ®Google Scholar
• Indhumathi S, Rajappa M, Chandrashekar L, Ananthanarayanan PH, Thappa DM, Negi VS. Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis. Eur J Clin Pharmacol. 2017;73(8):965–971. doi:10.1007/s00228-017-2255-x
   PubMed Web of Science ®Google Scholar
• Goldminz AM, Suárez-Fariñas M, Wang AC, Dumont N, Krueger JG, Gottlieb AB. CCL20 and IL22 messenger RNA expression after adalimumab vs methotrexate treatment of psoriasis: a randomized clinical trial. JAMA Dermatol. 2015;151(8):837–846. doi:10.1001/jamadermatol.2015.0452
   PubMed Web of Science ®Google Scholar
• Grželj J, Mlinarič-Raščan I, Marko PB, Marovt M, Gmeiner T, Šmid A. Polymorphisms in GNMT and DNMT3b are associated with methotrexate treatment outcome in plaque psoriasis. Biomed Pharmacother. 2021;138:111456. doi:10.1016/j.biopha.2021.111456
   PubMed Web of Science ®Google Scholar
• Grželj J, Marovt M, Marko PB, Mlinarič-Raščan I, Gmeiner T, Šmid A. Polymorphism in gene for ABCC2 transporter predicts methotrexate drug survival in patients with psoriasis. Medicina. 2021;57(10):1050. doi:10.3390/medicina57101050
   PubMed Web of Science ®Google Scholar
• Fan Z, Zhang Z, Huang Q, et al. The impact of ANxA6 gene polymorphism on the efficacy of methotrexate treatment in psoriasis patients. Dermatology. 2021;237(4):579–587. doi:10.1159/000514072
   PubMed Web of Science ®Google Scholar
• West J, Ogston S, Berg J, et al. HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment. Clin Exp Dermatol. 2017;42(6):651–655. doi:10.1111/ced.13100
   PubMed Web of Science ®Google Scholar
• Chen W, Zhang X, Zhang W, Peng C, Zhu W, Chen X. Polymorphisms of SLCO1B1 rs4149056 and SLC22A1 rs2282143 are associated with responsiveness to Acitretin in psoriasis patients. Sci Rep. 2018;8(1):13182. doi:10.1038/s41598-018-31352-2
   PubMed Web of Science ®Google Scholar
• Young HS, Summers AM, Read IR, et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol. 2006;126(2):453–459. doi:10.1038/sj.jid.5700096
   PubMed Web of Science ®Google Scholar
• Chen W, Wu L, Zhu W, Chen X. The polymorphisms of growth factor genes (VEGFA & EGF) were associated with response to Acitretin in psoriasis. Per Med. 2018;15(3):181–188. doi:10.2217/pme-2017-0085
   PubMed Web of Science ®Google Scholar
• Campalani E, Allen MH, Fairhurst D, et al. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to Acitretin. Br J Dermatol. 2006;154(2):345–352. doi:10.1111/j.1365-2133.2005.06950.x
   PubMed Web of Science ®Google Scholar
• Zhou X, Zhu W, Shen M, et al. Frizzled-related proteins 4 (SFRP4) rs1802073G allele predicts the elevated serum lipid levels during Acitretin treatment in psoriatic patients from Hunan, China. PeerJ. 2018;6:e4637. doi:10.7717/peerj.4637
   PubMed Web of Science ®Google Scholar
• O’Rielly DD, Rahman P. Pharmacogenetics of psoriasis. Pharmacogenomics. 2011;12(1):87–101. doi:10.2217/pgs.10.166
   PubMed Web of Science ®Google Scholar
• Naesens M, Kuypers DRJ, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481–508. doi:10.2215/CJN.04800908
   PubMed Web of Science ®Google Scholar
• Vasilopoulos Y, Sarri C, Zafiriou E, et al. A pharmacogenetic study of ABCB1 polymorphisms and cyclosporine treatment response in patients with psoriasis in the Greek population. Pharmacogenomics J. 2014;14(6):523–525. doi:10.1038/tpj.2014.23
   PubMed Web of Science ®Google Scholar
• Haider AS, Lowes MA, Suárez-Fariñas M, et al. Identification of cellular pathways of “type 1,” Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol. 2008;180(3):1913–1920. doi:10.4049/jimmunol.180.3.1913
   PubMed Web of Science ®Google Scholar
• Caputo V, Strafella C, Cosio T, et al. Pharmacogenomics: an update on biologics and small-molecule drugs in the treatment of psoriasis. Genes. 2021;12(9):1398. doi:10.3390/genes12091398
   PubMed Web of Science ®Google Scholar
• Gambichler T, Susok L, Zankl J, Skrygan M. Val/Val glutathione-S-transferase P1 polymorphism predicts nonresponders in psoriasis patients treated with fumaric acid esters. Pharmacogenet Genomics. 2016;26(5):248–253. doi:10.1097/FPC.0000000000000218
   PubMed Web of Science ®Google Scholar
• Brownstone ND, Hong J, Mosca M, et al. Biologic treatments of psoriasis: an update for the clinician. Biologics. 2021;15:39–51. doi:10.2147/BTT.S252578
   PubMed Web of Science ®Google Scholar
• Udalova I, Monaco C, Nanchahal J, Feldmann M. Anti-TNF Therapy. Microbiol Spectr. 2016;4(4). doi:10.1128/microbiolspec.MCHD-0022-2015
   PubMed Web of Science ®Google Scholar
• Megna M, Fornaro L, Potestio L, et al. Efficacy and safety of anti-TNF Biosimilars for psoriasis in pediatric and geriatric populations: a 72-week real-life study. Psoriasis. 2022;12:199–204. doi:10.2147/PTT.S365493
   PubMed Web of Science ®Google Scholar
• Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology. 2010;49(7):1215–1228. doi:10.1093/rheumatology/keq031
   PubMed Web of Science ®Google Scholar
• Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993;30(16):1443–1453. doi:10.1016/0161-5890(93)90106-l
   PubMed Web of Science ®Google Scholar
• Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda APM. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72(4):517–524. doi:10.1136/annrheumdis-2011-201244
   PubMed Web of Science ®Google Scholar
• Caldarola G, Sgambato A, Fanali C, et al. HLA-Cw6 allele, NFkB1 and NFkBIA polymorphisms play no role in predicting response to etanercept in psoriatic patients. Pharmacogenet Genomics. 2016;26(9):423–427. doi:10.1097/FPC.0000000000000233
   PubMed Web of Science ®Google Scholar
• Ryan C, Kelleher J, Fagan MF, et al. Genetic markers of treatment response to tumour necrosis factor-α inhibitors in the treatment of psoriasis. Clin Exp Dermatol. 2014;39(4):519–524. doi:10.1111/ced.12323
   PubMed Web of Science ®Google Scholar
• Gallo E, Cabaleiro T, Román M, et al. The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study. Br J Dermatol. 2013;169(4):819–829. doi:10.1111/bjd.12425
   PubMed Web of Science ®Google Scholar
• Batalla A, Coto E, González-Fernández D, et al. The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients. Pharmacogenet Genomics. 2015;25(6):313–316. doi:10.1097/FPC.0000000000000136
   PubMed Web of Science ®Google Scholar
• Linares-Pineda TM, Cañadas-Garre M, Sánchez-Pozo A, Calleja-Hernández MÁ. Gene polymorphisms as predictors of response to biological therapies in psoriasis patients. Pharmacol Res. 2016;113:71–80. doi:10.1016/j.phrs.2016.07.020
   PubMed Web of Science ®Google Scholar
• Murdaca G, Gulli R, Spanò F, et al. TNF-α gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis. J Invest Dermatol. 2014;134(10):2503–2509. doi:10.1038/jid.2014.123
   PubMed Web of Science ®Google Scholar
• Vasilopoulos Y, Manolika M, Zafiriou E, et al. Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population. Mol Diagn Ther. 2012;16(1):29–34. doi:10.1007/BF03256427
   PubMed Web of Science ®Google Scholar
• van Vugt LJ, van den Reek JMPA, Coenen MJH, de Jong EMGJ. A systematic review of pharmacogenetic studies on the response to biologics in patients with psoriasis. Br J Dermatol. 2018;178(1):86–94. doi:10.1111/bjd.15753
   PubMed Web of Science ®Google Scholar
• Talamonti M, D’Adamio S, Bianchi L, Galluzzo M. The role of pharmacogenetics in chronic plaque psoriasis: update of the literature. Mol Diagn Ther. 2017;21(5):467–480. doi:10.1007/s40291-017-0274-z
   PubMed Web of Science ®Google Scholar
• Prieto-Pérez R, Cabaleiro T, Daudén E, Ochoa D, Roman M, Abad-Santos F. Genetics of psoriasis and pharmacogenetics of biological drugs. Autoimmune Dis. 2013;2013:613086. doi:10.1155/2013/613086
   PubMedGoogle Scholar
• Ovejero-Benito MC, Prieto-Pérez R, Llamas-Velasco M, et al. Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis. Pharmacogenomics. 2017;18(7):631–638. doi:10.2217/pgs-2017-0014
   PubMed Web of Science ®Google Scholar
• Julià A, Ferrándiz C, Dauden E, et al. Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis. Pharmacogenomics J. 2015;15(4):322–325. doi:10.1038/tpj.2014.71
   PubMed Web of Science ®Google Scholar
• Prieto-Pérez R, Solano-López G, Cabaleiro T, et al. New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis. Pharmacogenomics J. 2018;18(1):70–75. doi:10.1038/tpj.2016.64
   PubMed Web of Science ®Google Scholar
• Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum. 2005;52(9):2693–2696. doi:10.1002/art.21266
   PubMed Web of Science ®Google Scholar
• Tejasvi T, Stuart PE, Chandran V, et al. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol. 2012;132(3 Pt 1):593–600. doi:10.1038/jid.2011.376
   PubMed Web of Science ®Google Scholar
• Seitz M, Wirthmüller U, Möller B, Villiger PM. The −308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology. 2007;46(1):93–96. doi:10.1093/rheumatology/kel175
   PubMed Web of Science ®Google Scholar
• Coto-Segura P, Batalla A, González-Fernández D, et al. CDKAL1 gene variants affect the anti-TNF response among Psoriasis patients. Int Immunopharmacol. 2015;29(2):947–949. doi:10.1016/j.intimp.2015.11.008
   PubMed Web of Science ®Google Scholar
• Batalla A, Coto E, Gómez J, et al. IL17RA gene variants and anti-TNF response among psoriasis patients. Pharmacogenomics J. 2018;18(1):76–80. doi:10.1038/tpj.2016.70
   PubMed Web of Science ®Google Scholar
• Song GG, Seo YH, Kim J-H, Choi SJ, Ji JD, Lee YH. Association between TNF-α (−308 A/G, −238 A/G, −857 C/T) polymorphisms and responsiveness to TNF-α blockers in spondyloarthropathy, psoriasis and Crohn’s disease: a meta-analysis. Pharmacogenomics. 2015;16(12):1427–1437. doi:10.2217/pgs.15.90
   PubMed Web of Science ®Google Scholar
• Ovejero-Benito MC, Muñoz-Aceituno E, Sabador D, et al. Genome-wide association analysis of psoriasis patients treated with anti-TNF drugs. Exp Dermatol. 2020;29(12):1225–1232. doi:10.1111/exd.14215
   PubMed Web of Science ®Google Scholar
• Nishikawa R, Nagai H, Bito T, et al. Genetic prediction of the effectiveness of biologics for psoriasis treatment. J Dermatol. 2016;43(11):1273–1277. doi:10.1111/1346-8138.13412
   PubMed Web of Science ®Google Scholar
• Ovejero-Benito MC, Muñoz-Aceituno E, Sabador D, et al. Polymorphisms associated with optimization of biological therapy through drug dose reduction in moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2020;34(6):e271–e275. doi:10.1111/jdv.16256
   PubMed Web of Science ®Google Scholar
• Skarmoutsou E, Trovato C, Granata M, et al. Biological therapy induces expression changes in Notch pathway in psoriasis. Arch Dermatol Res. 2015;307(10):863–873. doi:10.1007/s00403-015-1594-7
   PubMed Web of Science ®Google Scholar
• Vageli DP, Exarchou A, Zafiriou E, Doukas PG, Doukas S, Roussaki-Schulze A. Effect of TNF-α inhibitors on transcriptional levels of pro-inflammatory interleukin-33 and Toll-like receptors-2 and −9 in psoriatic plaques. Exp Ther Med. 2015;10(4):1573–1577. doi:10.3892/etm.2015.2688
   PubMed Web of Science ®Google Scholar
• Pivarcsi A, Meisgen F, Xu N, Ståhle M, Sonkoly E. Changes in the level of serum microRNAs in patients with psoriasis after antitumour necrosis factor-α therapy. Br J Dermatol. 2013;169(3):563–570. doi:10.1111/bjd.12381
   PubMed Web of Science ®Google Scholar
• De Simone C, Farina M, Maiorino A, et al. TNF-alpha gene polymorphisms can help to predict response to etanercept in psoriatic patients. J Eur Acad Dermatol Venereol. 2015;29(9):1786–1790. doi:10.1111/jdv.13024
   PubMed Web of Science ®Google Scholar
• Prieto-Pérez R, Solano-López G, Cabaleiro T, et al. The polymorphism rs763780 in the IL-17F gene is associated with response to biological drugs in patients with psoriasis. Pharmacogenomics. 2015;16(15):1723–1731. doi:10.2217/pgs.15.107
   PubMed Web of Science ®Google Scholar
• Ustekinumab (STELARA). Prescribing information; 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761044lbl.pdf. Accessed February 11, 2022.
   Google Scholar
• Raposo I, Carvalho C, Bettencourt A, et al. Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab. Eur J Dermatol. 2017;27(5):528–530. doi:10.1684/ejd.2017.3071
   PubMed Web of Science ®Google Scholar
• Talamonti M, Galluzzo M, van den Reek JM, et al. Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients. Br J Dermatol. 2017;177(2):489–496. doi:10.1111/bjd.15387
   PubMed Web of Science ®Google Scholar
• van Vugt LJ, van den Reek JMPA, Hannink G, Coenen MJH, de Jong EMGJ. Association of HLA-C*06:02 status with differential response to ustekinumab in patients with psoriasis: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(6):708–715. doi:10.1001/jamadermatol.2019.0098
   PubMed Web of Science ®Google Scholar
• Anzengruber F, Ghosh A, Maul J-T, Drach M, Navarini AA. Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis. Psoriasis. 2017;8:7–11. doi:10.2147/PTT.S161437
   PubMedGoogle Scholar
• Prieto-Pérez R, Llamas-Velasco M, Cabaleiro T, et al. Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis. Pharmacogenomics. 2017;18(2):157–164. doi:10.2217/pgs-2016-0122
   PubMed Web of Science ®Google Scholar
• Loft ND, Skov L, Iversen L, et al. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis. Pharmacogenomics J. 2018;18(3):494–500. doi:10.1038/tpj.2017.31
   PubMed Web of Science ®Google Scholar
• Connell WT, Hong J, Liao W. Genome-wide association study of ustekinumab response in psoriasis. Front Immunol. 2021;12:815121. doi:10.3389/fimmu.2021.815121
   PubMed Web of Science ®Google Scholar
• van den Reek JMPA, Coenen MJH, van de L’Isle Arias M, et al. Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis. Br J Dermatol. 2017;176(5):1288–1296. doi:10.1111/bjd.15005
   PubMed Web of Science ®Google Scholar
• Brodmerkel C, Li K, Garcet S, et al. Modulation of inflammatory gene transcripts in psoriasis vulgaris: differences between ustekinumab and etanercept. J Allergy Clin Immunol. 2019;143(5):1965–1969. doi:10.1016/j.jaci.2019.01.017
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Boca AN, Botti E, et al. IL12B (p40) gene polymorphisms contribute to ustekinumab response prediction in psoriasis. Dermatology. 2016;232(2):230–236. doi:10.1159/000441719
   PubMed Web of Science ®Google Scholar
• Chiu H-Y, Wang T-S, Chan -C-C, Cheng Y-P, Lin S-J, Tsai T-F. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis. Br J Dermatol. 2014;171(5):1181–1188. doi:10.1111/bjd.13056
   PubMed Web of Science ®Google Scholar
• Dand N, Duckworth M, Baudry D, et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J Allergy Clin Immunol. 2019;143(6):2120–2130. doi:10.1016/j.jaci.2018.11.038
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Camela E, Fabbrocini G, Megna M. Bimekizumab for the treatment of psoriasis: a review of the current knowledge. Psoriasis. 2022;12:127–137. doi:10.2147/PTT.S367744
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Camela E, Fabbrocini G, Ruggiero A. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-center retrospective study in a real-life setting. Dermatol Ther. 2022;e15667. doi:10.1111/dth.15667
   PubMed Web of Science ®Google Scholar
• Costanzo A, Bianchi L, Flori ML, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br J Dermatol. 2018;179(5):1072–1080. doi:10.1111/bjd.16705
   PubMed Web of Science ®Google Scholar
• Papini M, Cusano F, Romanelli M, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study. Br J Dermatol. 2019;181(2):413–414. doi:10.1111/bjd.18013
   PubMed Web of Science ®Google Scholar
• Anzengruber F, Drach M, Maul J-T, Kolios AG, Meier B, Navarini AA. Therapy response was not altered by HLA-Cw6 status in psoriasis patients treated with secukinumab: a retrospective case series. J Eur Acad Dermatol Venereol. 2018;32(7):e274–e276. doi:10.1111/jdv.14808
   PubMed Web of Science ®Google Scholar
• van Vugt LJ, van den Reek JMPA, Meulewaeter E, et al. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. J Eur Acad Dermatol Venereol. 2020;34(1):112–118. doi:10.1111/jdv.15787
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. J Immunol. 2018;201(6):1605–1613. doi:10.4049/jimmunol.1800013
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Picone V, Marano L, Fabbrocini G, Marasca C. Paradoxical hidradenitis suppurativa during biologic therapy, an emerging challenge: a systematic review. Biomedicines. 2022;10(2):455. doi:10.3390/biomedicines10020455
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754–766. doi:10.1016/S0140-6736(21)00184-7
   PubMed Web of Science ®Google Scholar
• Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339–1350. doi:10.1038/jid.2009.59
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocini G, Cinelli E, Ocampo Garza SS, Camela E, Megna M. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Clin Exp Dermatol. 2022;47(3):561–567. doi:10.1111/ced.14979
   PubMed Web of Science ®Google Scholar
• Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022:1–8. doi:10.1080/09546634.2022.2081655
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. J Dermatolog Treat. 2022;1–5. doi:10.1080/09546634.2022.2036674
   PubMed Web of Science ®Google Scholar
• Yang Y, Xie S, Jiang W, Tang S, Shi Y. Discovering novel biomarkers associated with the pathogenesis of psoriasis: evidence from bioinformatic analysis. Int J Gen Med. 2022;15:2817–2833. doi:10.2147/IJGM.S354985
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Tsai T-F, Langley RG, et al. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: pooled analyses from the Phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. J Am Acad Dermatol. 2022;86(4):827–834. doi:10.1016/j.jaad.2021.11.004
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with Adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the Phase III, double-blinded, placebo- and active comparator. J Am Acad Dermatol. 2017;76(3):405–417. doi:10.1016/j.jaad.2016.11.041
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocini G, Cinelli E, Megna M. Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: a real-life 52-week retrospective study. Dermatol Ther. 2021;34(1):e14673. doi:10.1111/dth.14673
   PubMed Web of Science ®Google Scholar
• Megna M, Fabbrocini G, Cinelli E, Camela E, Ruggiero A. Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience. J Dermatolog Treat. 2022;33(2):1074–1078. doi:10.1080/09546634.2020.1800577
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocini G, Cinelli E, Megna M. Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison. J Am Acad Dermatol. 2021;85(4):1028–1030. doi:10.1016/j.jaad.2021.01.025
   PubMed Web of Science ®Google Scholar
• Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–661.
   PubMed Web of Science ®Google Scholar
• Augustin M, Lambert J, Zema C, et al. Effect of risankizumab on patient-reported outcomes in moderate to severe psoriasis: the ultimma-1 and ultimma-2 randomized clinical trials. JAMA Dermatol. 2020;156(12):1344–1353. doi:10.1001/jamadermatol.2020.3617
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Soliman AM, Yang H, et al. Impact of Risankizumab on PASI90 and DLQI0/1 duration in moderate-to-severe psoriasis: a post hoc analysis of four phase 3 clinical trials. Dermatol Ther. 2022;12(2):407–418. doi:10.1007/s13555-021-00660-3
   PubMed Web of Science ®Google Scholar
• Megna M, Cinelli E, Gallo L, Camela E, Ruggiero A, Fabbrocini G. Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period. Arch Dermatol Res. 2021;314:619–623. doi:10.1007/s00403-021-02200-7
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study. Dermatol Ther. 2022;35:e15524. doi:10.1111/dth.15524
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–288. doi:10.1016/S0140-6736(17)31279-5
   PubMed Web of Science ®Google Scholar
• Verbenko DA, Karamova AE, Artamonova OG, et al. Apremilast pharmacogenomics in Russian patients with moderate-to-severe and severe psoriasis. J Pers Med. 2020;11(1):20. doi:10.3390/jpm11010020
   PubMed Web of Science ®Google Scholar
• Bai F, Zheng W, Dong Y, et al. Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis. Oncotarget. 2018;9(1):1266–1278. doi:10.18632/oncotarget.22260
   PubMedGoogle Scholar
• Khashaba SA, Attwa E, Said N, Ahmed S, Khattab F. Serum YKL-40 and IL 17 in Psoriasis: reliability as prognostic markers for disease severity and responsiveness to treatment. Dermatol Ther. 2021;34(1):e14606. doi:10.1111/dth.14606
   PubMed Web of Science ®Google Scholar
• Olejniczak-Staruch I, Narbutt J, Bednarski I, et al. Interleukin 22 and 6 serum concentrations decrease under long-term biologic therapy in psoriasis. Postep dermatologii i Alergol. 2020;37(5):705–711. doi:10.5114/ada.2020.100481
   PubMed Web of Science ®Google Scholar
• Wang X, Kaiser H, Kvist-Hansen A, et al. IL-17 pathway members as potential biomarkers of effective systemic treatment and cardiovascular disease in patients with moderate-to-severe psoriasis. Int J Mol Sci. 2022;23(1). doi:10.3390/ijms23010555
   Web of Science ®Google Scholar
• Xu M, Deng J, Xu K, et al. In-depth serum proteomics reveals biomarkers of psoriasis severity and response to traditional Chinese medicine. Theranostics. 2019;9(9):2475–2488. doi:10.7150/thno.31144
   PubMed Web of Science ®Google Scholar
• Elgharib I, Khashaba SA, Elsaid HH, Sharaf MM. Serum elafin as a potential inflammatory marker in psoriasis. Int J Dermatol. 2019;58(2):205–209. doi:10.1111/ijd.14217
   PubMed Web of Science ®Google Scholar
• Divyapriya D, Priyadarssini M, Indhumathi S, Rajappa M, Chandrashekar L, Mohanraj PS. Evaluation of cytokine gene expression in psoriasis. Postep dermatologii i Alergol. 2021;38(5):858–865. doi:10.5114/ada.2021.110109
   PubMed Web of Science ®Google Scholar
• Timis TL, Orasan RI. Understanding psoriasis: role of miRNAs. Biomed Rep. 2018;9(5):367–374. doi:10.3892/br.2018.1146
   PubMed Web of Science ®Google Scholar
• Aydin B, Arga KY, Karadag AS. Omics-driven biomarkers of psoriasis: recent insights, current challenges, and future prospects. Clin Cosmet Investig Dermatol. 2020;13:611–625. doi:10.2147/CCID.S227896
   PubMed Web of Science ®Google Scholar
• El-Komy M, Amin I, El-Hawary MS, Saadi D, Shaker O. Upregulation of the miRNA-155, miRNA-210, and miRNA-20b in psoriasis patients and their relation to IL-17. Int J Immunopathol Pharmacol. 2020;34:2058738420933742. doi:10.1177/2058738420933742
   Web of Science ®Google Scholar
• Lättekivi F, Guljavina I, Midekessa G, et al. Profiling blood serum extracellular vesicles in plaque psoriasis and psoriatic arthritis patients reveals potential disease biomarkers. Int J Mol Sci. 2022;23(7):4005. doi:10.3390/ijms23074005
   PubMed Web of Science ®Google Scholar
• Wu R, Zeng J, Yuan J, et al. MicroRNA-210 overexpression promotes psoriasis-like inflammation by inducing Th1 and Th17 cell differentiation. J Clin Invest. 2018;128(6):2551–2568. doi:10.1172/JCI97426
   PubMed Web of Science ®Google Scholar
• Chen X-M, Yao D-N, Wang M-J, et al. Deep Sequencing of serum exosomal microRNA level in psoriasis vulgaris patients. Front Med. 2022;9:895564. doi:10.3389/fmed.2022.895564
   Web of Science ®Google Scholar
• Abdallah HY, Tawfik NZ, Soliman NH, Eldeen LAT. The lncRNA PRINS-miRNA-mRNA axis gene expression profile as a circulating biomarker panel in psoriasis. Mol Diagn Ther. 2022;26(4):451–465. doi:10.1007/s40291-022-00598-y
   PubMed Web of Science ®Google Scholar
• Qiao M, Li R, Zhao X, Yan J, Sun Q. Up-regulated lncRNA-MSX2P1 promotes the growth of IL-22-stimulated keratinocytes by inhibiting miR-6731-5p and activating S100A7. Exp Cell Res. 2018;363(2):243–254. doi:10.1016/j.yexcr.2018.01.014
   PubMed Web of Science ®Google Scholar
• Ciążyńska M, Olejniczak-Staruch I, Sobolewska-Sztychny D, Narbutt J, Skibińska M, Lesiak A. The role of NLRP1, NLRP3, and AIM2 inflammasomes in psoriasis: review. Int J Mol Sci. 2021;22(11):5898. doi:10.3390/ijms22115898
   PubMed Web of Science ®Google Scholar